Phosphorylation Site Page:
In vivo Characterization
Methods used to characterize site
mass spectrometry ( 1, 3, 4, 5, 6, 7)
Disease tissue studied:
brain cancer ( 5), neuroendocrine cancer ( 5)
Relevant cell line - cell type - tissue:
32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ~aa 525-695 ETILLNS...IFEYCC)] ( 7), brain ( 5), liver ( 4), liver [leptin (mouse), homozygous knockout] ( 4), macrophage-peritoneum ( 3), macrophage-peritoneum [RIP3 (mouse), homozygous knockout] ( 3), MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 6), RAW 264.7 (macrophage) ( 1)
RIP3 (mouse) ( 3)
Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling.
Proteomics 15, 532-44
Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.
Mol Cell Proteomics 13, 1690-704
Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics.
Mol Cell Proteomics 11, 1640-51
Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis.
Cell Metab 16, 672-83
Guo A (2011)
CST Curation Set: 12730; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.
Science 332, 1317-22
Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
Mol Cell 36, 326-39